Rodolphe Barrangou Ph.D. is the T. R. Klaenhammer Distinguished Professor at North Carolina State University. Barrangou is focusing on the characterization of CRISPR-Cas systems, and their applications in bacteria, especially their use for the study and development of probiotics, including for genotyping, phage resistance, screening, genome editing and antimicrobials.
Rodolphe spent 9 years in R&D and M&A at Danisco and DuPont, and has been at NC State since 2013. For his CRISPR work, Rodolphe received several international awards, notably the Canada Gairdner International Award, and was elected into the National Academy of Sciences, the National Academy of Engineering, and the National Academy of Inventors.
Dr. Barrangou earned a BS in Biological Sciences from Rene Descartes University, France, a MS in Biological Engineering from the University of Technology in Compiegne, France, a MS in Food Science from NC State, a PhD in Genomics from NC State and a MBA from the University of Wisconsin-Madison.
Dr. Barrangou is also the former Chairman of the Board of Caribou Biosciences, a co-founder of Intellia Therapeutics, Locus Biosciences, TreeCo, Ancilia Biosciences and CRISPR Biotechnologies, an advisor to Inari Ag, Invaio, Provaxus, Felix Biotech, the IGI, and the Editor in Chief of the CRISPR Journal.